Literature DB >> 22033338

Axonal protein synthesis: a potential target for pain relief?

Ilona Obara1, Sandrine M Géranton, Stephen P Hunt.   

Abstract

Research on the role of axonal protein synthesis in the regulation of nociceptive mechanisms has grown significantly over the past four years. Recent advances include evidence that local translation of mRNA can occur in adult primary afferents under the control of the mammalian target of rapamycin (mTOR) and the extracellular signal-regulated kinase (ERK) signaling pathways. Studies investigating the effect of mTOR and ERK pathway inhibitors in a number of pain models suggest that these signaling pathways may act independently, depending on the type of sensory afferents studied. The evidence that nociception can be regulated at the level of mRNA translation in nociceptors has important implications for the understanding of the mechanisms of nociceptive plasticity and therefore for therapeutic interventions in chronic pain conditions. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033338     DOI: 10.1016/j.coph.2011.10.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  27 in total

Review 1.  Neuronal transient receptor potential (TRP) channels and noxious sensory detection in sickle cell disease.

Authors:  Katelyn E Sadler; Cheryl L Stucky
Journal:  Neurosci Lett       Date:  2018-11-30       Impact factor: 3.046

Review 2.  AMPK: An emerging target for modification of injury-induced pain plasticity.

Authors:  Theodore J Price; Gregory Dussor
Journal:  Neurosci Lett       Date:  2013-07-03       Impact factor: 3.046

3.  New trends in pain research: from basic research to clinical translation.

Authors:  Laura Berliocchi; Maria Maiarù; Damiana Scuteri; Maria Tiziana Corasaniti; Giacinto Bagetta
Journal:  Funct Neurol       Date:  2012 Oct-Dec

4.  Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.

Authors:  Raehannah J Jamshidi; Laura C Sullivan; Blaine A Jacobs; Teresa A Chavera; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-07       Impact factor: 4.030

Review 5.  Targeting AMPK for the Alleviation of Pathological Pain.

Authors:  Marina N Asiedu; Gregory Dussor; Theodore J Price
Journal:  Exp Suppl       Date:  2016

6.  Nociceptor Translational Profiling Reveals the Ragulator-Rag GTPase Complex as a Critical Generator of Neuropathic Pain.

Authors:  Salim Megat; Pradipta R Ray; Jamie K Moy; Tzu-Fang Lou; Paulino Barragán-Iglesias; Yan Li; Grishma Pradhan; Andi Wanghzou; Ayesha Ahmad; Michael D Burton; Robert Y North; Patrick M Dougherty; Arkady Khoutorsky; Nahum Sonenberg; Kevin R Webster; Gregory Dussor; Zachary T Campbell; Theodore J Price
Journal:  J Neurosci       Date:  2018-11-20       Impact factor: 6.167

7.  Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.

Authors:  Huijing Wang; Cobi J Heijnen; Cindy T J van Velthoven; Hanneke L D M Willemen; Yoshihiro Ishikawa; Xinna Zhang; Anil K Sood; Anne Vroon; Niels Eijkelkamp; Annemieke Kavelaars
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

Review 8.  From Mechanism to Cure: Renewing the Goal to Eliminate the Disease of Pain.

Authors:  Theodore J Price; Michael S Gold
Journal:  Pain Med       Date:  2018-08-01       Impact factor: 3.750

Review 9.  Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain.

Authors:  Theodore J Price; Vaskar Das; Gregory Dussor
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

10.  Peripheral administration of translation inhibitors reverses increased hyperalgesia in a model of chronic pain in the rat.

Authors:  Luiz F Ferrari; Oliver Bogen; Carissa Chu; Jon D Levine
Journal:  J Pain       Date:  2013-05-08       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.